OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Yan Xiong, Yue Zhong, Hyerin Yim, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 49, pp. 22622-22632
Open Access | Times Cited: 70
Yan Xiong, Yue Zhong, Hyerin Yim, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 49, pp. 22622-22632
Open Access | Times Cited: 70
Showing 51-75 of 70 citing articles:
Coming of Age: Targeting Cyclin K in Cancers
Yi Xiao, Jixin Dong
Cells (2023) Vol. 12, Iss. 16, pp. 2044-2044
Open Access | Times Cited: 4
Yi Xiao, Jixin Dong
Cells (2023) Vol. 12, Iss. 16, pp. 2044-2044
Open Access | Times Cited: 4
Lysosome and related protein degradation technologies
Hongmei Zheng, Gangjian Li, Jingli Min, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103767-103767
Closed Access | Times Cited: 4
Hongmei Zheng, Gangjian Li, Jingli Min, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103767-103767
Closed Access | Times Cited: 4
Discovery of the First-in-class G9a/GLP PROTAC Degrader
Julia Velez, Yulin Han, Hyerin Yim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Julia Velez, Yulin Han, Hyerin Yim, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Recent breakthroughs in innovative elements, multidimensional enhancements, derived technologies, and novel applications of PROTACs
Si-Han Zhang, Na Zeng, Jin‐Zhou Xu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117584-117584
Open Access | Times Cited: 1
Si-Han Zhang, Na Zeng, Jin‐Zhou Xu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117584-117584
Open Access | Times Cited: 1
Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor
Chunlan Pu, Yuanyuan Liu, Suke Lan, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 115, pp. 117970-117970
Closed Access | Times Cited: 1
Chunlan Pu, Yuanyuan Liu, Suke Lan, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 115, pp. 117970-117970
Closed Access | Times Cited: 1
Development of dual aptamers-functionalized c-MET PROTAC degraders for targeted therapy of osteosarcoma
Xuekun Fu, Jie Huang, Xinxin Chen, et al.
Theranostics (2024) Vol. 15, Iss. 1, pp. 103-121
Closed Access | Times Cited: 1
Xuekun Fu, Jie Huang, Xinxin Chen, et al.
Theranostics (2024) Vol. 15, Iss. 1, pp. 103-121
Closed Access | Times Cited: 1
Discovery of HyT‐Based Degraders of CDK9‐Cyclin T1 Complex
Rongkun Lin, Jie Yang, Ting Liu, et al.
Chemistry & Biodiversity (2023) Vol. 20, Iss. 8
Open Access | Times Cited: 2
Rongkun Lin, Jie Yang, Ting Liu, et al.
Chemistry & Biodiversity (2023) Vol. 20, Iss. 8
Open Access | Times Cited: 2
Amphiphilic Affibody-Protac Conjugate Self-Assembled Nanoagents for Targeted Cancer Therapy
Wenhui Gao, Xuelin Xia, Xiaoyuan Yang, et al.
(2024)
Closed Access
Wenhui Gao, Xuelin Xia, Xiaoyuan Yang, et al.
(2024)
Closed Access
Natural Compound‐Rhein and PROTACs Unleash Potent VEGFR‐2 Degraders
Ziqing Zhang, Meng Xu, Ruling Shi, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 8
Closed Access
Ziqing Zhang, Meng Xu, Ruling Shi, et al.
Chemistry & Biodiversity (2024) Vol. 21, Iss. 8
Closed Access
Synthesis and identification of a selective FGFR2 degrader with potent antiproliferative effects in gastric cancer
Zhanzhan Feng, Shirui Wang, Su Jong Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116780-116780
Closed Access
Zhanzhan Feng, Shirui Wang, Su Jong Yu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116780-116780
Closed Access
DNA-templated spatially controlled proteolysis targeting chimeras for CyclinD1-CDK4/6 complex protein degradation
Rong Zheng, Abhay Prasad, Deeksha Satyabola, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Rong Zheng, Abhay Prasad, Deeksha Satyabola, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access
Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer
S. Wu, Junnan Xu, Yiwen Ma, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
S. Wu, Junnan Xu, Yiwen Ma, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Design of Murine Double Minute 2 Proteolysis Targeting Chimera Degraders with a Built-In Tumor-Targeting Ability
Zhuqian Wang, Siran Yue, Xinxin Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18865-18882
Closed Access
Zhuqian Wang, Siran Yue, Xinxin Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 21, pp. 18865-18882
Closed Access
Palbociclib, ribociclib, and abemaciclib: potent and selective CDK4/6 inhibitors for the treatment of breast cancer
Kai Yuan, Weijiao Chen, Xiao Wang, et al.
Elsevier eBooks (2024), pp. 399-429
Closed Access
Kai Yuan, Weijiao Chen, Xiao Wang, et al.
Elsevier eBooks (2024), pp. 399-429
Closed Access
Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities
Shuqing Li, Wanyi Pan, Chengpeng Tao, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Shuqing Li, Wanyi Pan, Chengpeng Tao, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
PROTACs of cyclin-dependent kinases
Denisa Veselá, Eva Řezníčková, Václav Mik, et al.
Annual reports in medicinal chemistry (2024)
Closed Access
Denisa Veselá, Eva Řezníčková, Václav Mik, et al.
Annual reports in medicinal chemistry (2024)
Closed Access
Recent Advances in Developing Targeted Protein Degraders
Binbin Cheng, Hongqiao Li, Xiaopeng Peng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117212-117212
Closed Access
Binbin Cheng, Hongqiao Li, Xiaopeng Peng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117212-117212
Closed Access
Discovery of small molecule degraders for modulating cell cycle
Liguo Wang, Zhouli Yang, Guangchen Li, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 5, pp. 823-854
Closed Access | Times Cited: 1
Liguo Wang, Zhouli Yang, Guangchen Li, et al.
Frontiers of Medicine (2023) Vol. 17, Iss. 5, pp. 823-854
Closed Access | Times Cited: 1
MEK1/2-Targeting PROTACs Promote the Collateral Degradation of CRAF in KRAS Mutant Cells
Carlos Herrera-Montávez, Alison Kurimchak, Xiaoping Hu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Carlos Herrera-Montávez, Alison Kurimchak, Xiaoping Hu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Simple and Efficient Synthesis of Piperidine-2,6-Diones
Yuehua Liu, Zhang-Qin Xue, Kai-Wen Yang, et al.
(2023)
Closed Access
Yuehua Liu, Zhang-Qin Xue, Kai-Wen Yang, et al.
(2023)
Closed Access
